[{"orgOrder":0,"company":"Prorelix Research","sponsor":"Prorelix Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"NUV001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Prorelix Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Prorelix Research \/ Prorelix Research","highestDevelopmentStatusID":"1","companyTruncated":"Prorelix Research \/ Prorelix Research"},{"orgOrder":0,"company":"Prorelix Research","sponsor":"Prorelix Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Prorelix Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prorelix Research \/ Prorelix Research","highestDevelopmentStatusID":"1","companyTruncated":"Prorelix Research \/ Prorelix Research"},{"orgOrder":0,"company":"Prorelix Research","sponsor":"Prorelix Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Viracide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Prorelix Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prorelix Research \/ Prorelix Research","highestDevelopmentStatusID":"1","companyTruncated":"Prorelix Research \/ Prorelix Research"}]

Find Clinical Drug Pipeline Developments & Deals by Prorelix Research

Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          March 30, 2023

                          Lead Product(s) : NUV001

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Recipient : LGD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 30, 2021

                          Lead Product(s) : Nicotinamide Mononucleotide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Recipient : Abinopharm Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 22, 2020

                          Lead Product(s) : Viracide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Recipient : The Herb, Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank